Fusion Pharmaceuticals Inc. stock is up 45.94% since 30 days ago. The next earnings date is Mar 14, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 3 December’s closed higher than November. In the last 1 Unusual Options Trades, there were 1 CALL.
Fusion Pharmaceuticals Inc. focuses on developing radiopharmaceuticals as precision medicines. Its lead product candidate is FPI-1434 that is in Phase 1 clinical trials as a monotherapy in patients with solid tumors expressing insulin-like growth factor 1 receptor.